文献速递浆细胞疾病造血干细胞移植与细胞治疗

靶向HLA-E[pHLA-G]复合物的单克隆抗体增强多发性骨髓瘤中的NK细胞活性

HLA-E[pHLA-G] complex-specific monoclonal antibody enhancing NK activity in multiple myeloma.
PubMed 文献 · Blood Adv · 2025-01-01

研究开发了选择性靶向HLA-E[pHLA-G]复合物的单克隆抗体4D7,在多发骨髓瘤患者骨髓样本中特异性识别肿瘤相关HLA-E-肽复合物,阻断HLA-E:NKG2A相互作用并增强NKG2A阳性NK细胞活性,且不影响NKG2C阳性NK细胞;在荷MM小鼠中显著减少肿瘤生长,可能较现有NKG2A抑制剂降低毒性。

要点

  • 4D7特异性识别多发性骨髓瘤患者骨髓中的肿瘤相关HLA-E-肽复合物。
  • 4D7阻断HLA-E:NKG2A相互作用,增强NKG2A阳性NK细胞活性,不抑制NKG2C阳性NK细胞。
  • 在荷MM小鼠中,4D7联合人NK细胞显著减少肿瘤生长。

核心结论

  • 4D7是一种选择性靶向HLA-E[pHLA-G]复合物的单克隆抗体,可能较现有NKG2A抑制剂降低毒性,为多发性骨髓瘤免疫治疗提供有前景的进展。

研究设计与样本

  • 研究开发了新型免疫检查点抑制剂4D7,一种选择性靶向HLA-E[pHLA-G]复合物的单克隆抗体,并在多发性骨髓瘤患者骨髓样本、健康供者NK细胞及荷MM小鼠中进行验证。

主要发现

  • 在多发骨髓瘤患者临床骨髓样本中,4D7特异性识别肿瘤相关HLA-E-肽复合物。
  • 使用健康供者NK细胞,4D7有效阻断HLA-E:NKG2A相互作用,并在自体MM细胞共培养中增强NKG2A阳性NK细胞活性。
  • 4D7不抑制NKG2C阳性NK细胞,保留其活性,即使NKG2C也与HLA-E相互作用。
  • 在荷MM小鼠接受人NK细胞治疗时,4D7显著减少肿瘤生长。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

HLA-E presenting the HLA-G leader peptide VMAPRTLFL (HLA-E[pHLA-G]) on tumor cells plays a crucial role in suppressing natural killer (NK) and cytotoxic CD8+ T cells through NKG2A interaction. While blocking HLA-E:NKG2A is a promising immune checkpoint (IC) approach in cancer therapy, toxicity remains a major clinical concern. We developed a novel IC inhibitor that selectively prevents HLA-E:NKG2A interaction, a monoclonal antibody that selectively targets the HLA-E[pHLA-G] complex, distinguishing cancerous from noncancerous cells. In clinical bone marrow samples from patients with multiple myeloma (MM), 4D7 specifically recognized tumor-associated HLA-E-peptide complexes. Using NK cells from healthy donors, 4D7 effectively blocked the HLA-E:NKG2A interaction, and enhanced NKG2A-positive NK cell activity in autologous MM cell cocultures. Importantly, 4D7 did not inhibit NKG2C-positive NK cells, preserving their activity, even though NKG2C also interacts with HLA-E. In MM-bearing mice treated with human NK cells, 4D7 significantly reduced tumor growth. This targeted approach activates NK cells only against tumor cells presenting HLA-E-peptide complexes, potentially minimizing toxicity compared with current NKG2A inhibitors. The development of 4D7 highlights a promising advancement in immunotherapy for hematologic malignancies, offering improved outcomes for patients with MM, and a foundation for broader application across cancer types.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ahmad MA, Radinsky O, Kaufman B, et al. HLA-E[pHLA-G] complex-specific monoclonal antibody enhancing NK activity in multiple myeloma. Blood Adv. 2025. PMID: 40706037. doi:10.1182/bloodadvances.2025016276

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。